$MDCX

Medicus Pharma (MDCX) will focus its SkinJect asset development on Gorlin syndrome patients with multiple basal cell carcinoma lesions, abandoning other indications. The shift follows regulatory feedback and commercial assessments, aiming to resolve FDA concerns. The U.S. market for Gorlin syndrome treatments is estimated at $1.1 billion, with potential peak revenues of $383 million. MDCX shares fell 2.23% premarket on Monday.

Medicus Pharma Ltd. (MDCX) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02. Termination of a Material Definitive Agreement. On September 11, 2026, Medicus Pharma Ltd. (the "Company") and YA II PN, LTD. ("Yorkville") mutually agreed to terminate the Standby Equity Purchase Agreement, dated as of February 10, 2025, between the Company and Yorkvi

Medicus Pharma (MDCX) reported progress in its SkinJect program, confirming a 200-microgram patch dose for further studies. The company is focusing on Gorlin syndrome and seeking a partner for nodular basal cell carcinoma. A potential partnership could bring $25,000+ in reimbursement. Additionally, MDCX is collaborating with Pfizer on a CD228-targeted antibody-drug conjugate for melanoma and solid tumors, receiving $2M in funding.

Medicus Pharma Ltd. (MDCX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On September 4, 2026, Medicus Pharma Ltd. (the "Company") awarded cash bonuses in the aggregate amount of approximately $1.45 million to certain officers and employees of the Company. Each of the recipients elected to forgo payme

Medicus Pharma (MDCX) reported positive Phase 2 trial results for SkinJect in treating skin cancer, with all 90 patients completing treatment. The company plans to advance a 200-microgram dose in a registrational trial for Gorlin syndrome and seek a partner for broader use. The FDA cleared the SKNJCT-005 study, with potential peak US revenue estimated at $383 million.

Medicus Pharma (MDCX) is shifting its focus to CD228V, an antibody-drug conjugate for solid tumors, with initial trials targeting melanoma. The company is also refining strategies for SkinJect and Teverelix, prioritizing Gorlin syndrome and acute urinary retention. CEO Dr. Raza Bokhari stated the changes aim to enhance long-term growth. Shares rose 5.1% on Tuesday.

Medicus Pharma (MDCX) updated its strategy, focusing on CD228V, a second-generation antibody-drug conjugate for precision oncology. The company aims to prove its effectiveness in melanoma and pursue partnerships for other programs. CD228V is in a Phase 1 clinical trial.

Medicus Pharma Ltd. (MDCX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 2, 2026, Medicus Pharma Ltd. (the "Company"), through its wholly owned subsidiary, Medicus Pharma Inc., entered into a Co-Development and License Agreement (the "Agreement") with Pfizer Inc. ("Pfizer"). Under the

Thursday, the S&P 500 closed up 0.7% at a record 7,799, after briefly topping 7,800, as softer inflation data eased expectations for additional Fed rate hikes. The Nasdaq rose 0.8% to 26,803. Investors also looked ahead to earnings, including Applied Materials after the close.

Medicus Pharma (NASDAQ:MDCX) reported Q2 2026 progress in its SkinJect and Teverelix programs, including FDA “Study May Proceed” for a registrational SkinJect study in Gorlin Syndrome and UAE/IRB approvals for Teverelix Phase 2 work. Cash was $25.2M at June 30. Net loss was $11.7M ($0.21/share). The company raised about $40M in H1 2026 and warned of going-concern risk.